Dr. Till is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 855-557-0555Fax+1 206-606-1025- Is this information wrong?
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2002 - 2005
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2002
Certifications & Licensure
WA State Medical License 2005 - 2025
PA State Medical License 2002 - 2005- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2012 Aug 09
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2018 Mar 06
Roles: Principal Investigator
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Start of enrollment: 2017 Dec 05
Publications & Presentations
PubMed
- 1 citationsTiming of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.Alexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, Salvatore Fiorenza, Jordan Gauthier, Jenna M Voutsinas, Qian Wu, Cecilia C S Yeung, Nicolas Gazeau, Barbara S Pe...> ;Blood Advances. 2024 Jan 23
- Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.Banerjee, R., Hirayama, A., Gauthier, J., Cassaday, R., Shadman, M., Cowan, A., Till, B., Green, D., Kiem, H., Gopal, A., Maloney, D., Banerjee, R., Poh, C.> ;Blood Advances. 2024 Feb 27
- 2 citationsFactors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.Emily C Liang, Aya Albittar, Jennifer J Huang, Alexandre V Hirayama, Erik L Kimble, Andrew J Portuguese, Aude Chapuis, Mazyar Shadman, Brian G Till, Ryan D Cassaday, F...> ;Blood Advances. 2023 Nov 28
- Join now to see all
Abstracts/Posters
- Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ...Brian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell TherapyBrian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin LymphomasBrian G. Till, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
- Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual MeetingNovember 4th, 2020
Hospital Affiliations
Fred Hutchinson Cancer CenterSeattle, Washington
UW Medicine/University of Washington Medical CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
